About
Pimyupa Manaswiyoungkul, PhD is a co-founder and COO of HDAX Therapeutics, a Canadian biotech developing HDAC6-targeting small-molecule therapeutics for neurological and cardiometabolic diseases. HDAX states the company originated from Professor Patrick Gunning's lab at the University of Toronto, and third-party ecosystem profiles list Manaswiyoungkul on the founding leadership team. She also appears as a co-author on a 2022 EMBO Molecular Medicine paper, indicating a scientific research background alongside her operating role.
Areas of interest
biotechdrug discoveryprecision therapeuticsneurologycardiometabolic diseaseoncologylife sciences